Skip to main content

Table 1 Between-group comparison of baseline data

From: Comparing the vascular thromboembolic events following arteriovenous fistula in Chinese population with end-stage renal diseases receiving Clopidogrel versus Beraprost sodium therapy: a retrospective cohort study

Variable

CL (n = 112)

BPS (n = 110)

P - value

Age (y)

  

0.73*a

 20–39

35

33

 

 40–59

44

42

 

 60–79

33

35

 

Sex, No. M/F

60/52

59/51

0.99*b

Systolic BP (mmHg)

167.13 ± 31.47

166.87 ± 34.79

0.15*c

Diastolic BP (mmHg)

102.52 ± 25.46

103.24 ± 23.47

0.22*c

Hypertension, No.

82

84

0.59*b

Hb (g/dL)

12.14 ± 1.35

12.36 ± 1.12

0.15*c

BUN (mg/dL)

43.37 ± 15.31

42.83 ± 17.68

0.16*c

eGFR (ml/min/1.73 m2)

13.15 ± 3.43

13.45 ± 3.62

0.48*c

Creatinine (mg/dL)

10.71 ± 1.48

10.42 ± 1.32

0.27*c

Dialysis duration with respective access (months)

14.22 ± 7.35

14.68 ± 7.22

0.18*c

Type dialysis, No.

  

0.37*b

 Haemodialysis

107

102

 

 Peritoneal dialysis

5

8

 

Ambulatory status

  

0.47*a

 Normal walking

103

98

 

 Walking with assistive devices

9

12

 

 Completely restricted walking

0

0

 

ASA level

  

0.94*a

 1

31

34

 

 2

47

40

 

 3

34

36

 

BMD

−2.57 ± 0.34

−2.49 ± 0.52

0.47*c

BMI (kg/m2)

24.71 ± 4.34

25.12 ± 4.61

0.36*c

Personal history of VTEs

16/112

18/110

0.67*b

Family history of VTEs

12/112

14/110

0.64*b

Diabetes mellitus

 Duration, year

19 (4–26)

18 (5–24)

0.14*c

 Type 2, No.

27

29

0.70*b

 Insulin use, No.

15

17

0.66*b

  1. CL clopidogrel, BPS beraprost sodium, BP blood pressure, Hb haemoglobin, BUN blood urea nitrogen, eGFR estimated glomerular filtration rate, ASA American Society of Anesthesiologists, BMD bone mineral density, BMI body mass index, VTEs vascular thromboembolic events
  2. *No statistically significant values
  3. aAnalysed using the Mann-Whitney test
  4. bAnalysed using the Chi-square test
  5. cAnalysed using an Independent-Samples t-test